Weight and Body Mass Index for Predicting Thyroxine Dose in Primary Hypothyroidism

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Jun 17

PMID 34136323

Authors

Kashif Raashid

Osama Ishtiaq

Matiullah Kamin

Tejhmal Rehman

Sajjad Ali Khan

Umar Raja

Fazal H Shah

Affiliations

Soon will be listed here.

Abstract

Background The treatment of primary hypothyroidism with thyroxine is weight-based or body mass index (BMI)-based. However, significant variation in the dose and the consequent delay in achieving euthyroid state is observed along the spectrum of patient body weights. Objectives To determine the weight and BMI-based dosing of thyroxine in primary hypothyroidism to achieve euthyroidism Material and methods It was a retrospective review of the patient records conducted in the department of endocrinology, Shifa International Hospital, Islamabad, from July 1, 2014, to June 30, 2019 (five-year period) Patients with clinical and biochemical hypothyroidism were enrolled and initiated on thyroxine replacement to achieve euthyroid status. A total of 504 patients were included in the study. Results The mean age was 44.5 ±13.6 standard deviation. Females were 83.5%. The mean dose of thyroxine to achieve euthyroid status was 107.7 ± 39.3 mean standard deviation mcg/day, i.e. 1.4 (0.5) mcg/kg/day. Euthyroid status was achieved in 264 (52.4%) of patients at three months. The mean TSH level after treatment was 2.09 (1.2) mU/L. The linear regression model showed that BMI and weight are independent predictors of the required thyroxine dose (R and Rsquare values are .274 and 0.075 for BMI and .319 and .102 for weight, respectively (P-value <.0001). There was no impact of age, gender, height, and duration of disease on achieving euthyroid at six months after treatment (P values: .85, .394, .827, and .105, respectively). Conclusion The optimum dose in primary hyperthyroidism can be determined with body weight and BMI-based calculations.

References

Chen S, Zaborek N, Doubleday A, Schaefer S, Long K, Pitt S . Optimizing Levothyroxine Dose Adjustment After Thyroidectomy With a Decision Tree. J Surg Res. 2019; 244:102-106. PMC: 7041547. DOI: 10.1016/j.jss.2019.06.025. View

Duntas L, Jonklaas J . Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime. Adv Ther. 2019; 36(Suppl 2):30-46. PMC: 6822824. DOI: 10.1007/s12325-019-01078-2. View

Jonklaas J, Tefera E, Shara N . Physician Choice of Hypothyroidism Therapy: Influence of Patient Characteristics. Thyroid. 2018; 28(11):1416-1424. PMC: 6247977. DOI: 10.1089/thy.2018.0325. View

Tan N, Chew R, Koh Y, Subramanian R, Sankari U, Meyappan M . Primary hypothyroidism in the community: Lower daily dosages of levothyroxine replacement therapy for Asian patients. Medicine (Baltimore). 2017; 96(7):e6145. PMC: 5319534. DOI: 10.1097/MD.0000000000006145. View

Midgley J, Toft A, Larisch R, Dietrich J, Hoermann R . Time for a reassessment of the treatment of hypothyroidism. BMC Endocr Disord. 2019; 19(1):37. PMC: 6471951. DOI: 10.1186/s12902-019-0365-4. View

Di Donna V, Giannotti Santoro M, de Waure C, Ricciato M, Paragliola R, Pontecorvi A . A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014; 24(12):1759-64. DOI: 10.1089/thy.2014.0111. View

Jonklaas J, Bianco A, Bauer A, Burman K, Cappola A, Celi F . Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12):1670-751. PMC: 4267409. DOI: 10.1089/thy.2014.0028. View

Jonklaas J . Update on the treatment of hypothyroidism. Curr Opin Oncol. 2015; 28(1):18-25. PMC: 4699420. DOI: 10.1097/CCO.0000000000000242. View

Mateo R, Hennessey J . Thyroxine and treatment of hypothyroidism: seven decades of experience. Endocrine. 2019; 66(1):10-17. PMC: 6794242. DOI: 10.1007/s12020-019-02006-8. View

10.

Benvenga S, Carle A . Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution. Adv Ther. 2019; 36(Suppl 2):59-71. PMC: 6822816. DOI: 10.1007/s12325-019-01079-1. View

11.

Chiovato L, Magri F, Carle A . Hypothyroidism in Context: Where We've Been and Where We're Going. Adv Ther. 2019; 36(Suppl 2):47-58. PMC: 6822815. DOI: 10.1007/s12325-019-01080-8. View

12.

McAninch E, Bianco A . The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy. Front Endocrinol (Lausanne). 2019; 10:446. PMC: 6629976. DOI: 10.3389/fendo.2019.00446. View

13.

Zaborek N, Cheng A, Imbus J, Long K, Pitt S, Sippel R . The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation. Surgery. 2018; 165(1):92-98. PMC: 6289766. DOI: 10.1016/j.surg.2018.04.097. View

14.

Laurberg P, Andersen S, Bulow Pedersen I, Carle A . Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging. 2005; 22(1):23-38. DOI: 10.2165/00002512-200522010-00002. View

15.

Kumar R, Shaukat F . Adherence to Levothyroxine Tablet in Patients with Hypothyroidism. Cureus. 2019; 11(5):e4624. PMC: 6615580. DOI: 10.7759/cureus.4624. View

16.

Biondi B, Cooper D . Thyroid hormone therapy for hypothyroidism. Endocrine. 2019; 66(1):18-26. DOI: 10.1007/s12020-019-02023-7. View

17.

Mistry D, Atkin S, Atkinson H, Gunasekaran S, Sylvester D, Rigby A . Predicting thyroxine requirements following total thyroidectomy. Clin Endocrinol (Oxf). 2011; 74(3):384-7. DOI: 10.1111/j.1365-2265.2010.03940.x. View

18.

Ojomo K, Schneider D, Reiher A, Lai N, Schaefer S, Chen H . Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg. 2013; 216(3):454-60. PMC: 3658157. DOI: 10.1016/j.jamcollsurg.2012.12.002. View

19.

Al-Dhahri S, Al-Angari S, Alharbi J, Alessa M . Optimal levothyroxine dose in post-total thyroidectomy patients: a prediction model for initial dose titration. Eur Arch Otorhinolaryngol. 2019; 276(9):2559-2564. DOI: 10.1007/s00405-019-05523-4. View